Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Debt / NOTE 3.500% 9/1
-
Market price (% of par)
-
153.88%
-
Total 13F principal
-
$98,703,000
-
Principal change
-
+$4,839,000
-
Total reported market value
-
$151,622,681
-
Number of holders
-
12
-
Value change
-
+$1,877,380
-
Number of buys
-
5
-
Number of sells
-
5
Institutional Holders of APELLIS PHARMACEUTICALS INC - NOTE 3.500% 9/1 as of Q4 2022
As of 31 Dec 2022,
APELLIS PHARMACEUTICALS INC - NOTE 3.500% 9/1 was held by
12 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$98,703,000
in principal (par value) of the bond.
The largest 10 bondholders included
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), LAZARD ASSET MANAGEMENT LLC, WOLVERINE ASSET MANAGEMENT LLC, LORD, ABBETT & CO. LLC, LORD, ABBETT & CO. LLC, WELLINGTON MANAGEMENT GROUP LLP, PALISADE CAPITAL MANAGEMENT, LP, KORNITZER CAPITAL MANAGEMENT INC /KS, JPMORGAN CHASE & CO, and MACKAY SHIELDS LLC.
This page lists
13
institutional bondholders reporting positions
for the Q4 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.